Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Hemocompatibility of the Direct Oral Anti-Coagulant Apixaban in Left Ventricular Assist Devices

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients implanted with a HeartMate 3 LVAD~2. Age 18 or greater and able to provide written informed consent~3. Females of childbearing age must agree to adequate contraception~Exclusion Criteria:~1. History of post-LVAD device thrombosis, stroke, or gastrointestinal bleeding~2. Patients who are bridge to transplant and a current UNOS status 1-3~3. Ongoing inotrope therapy after LVAD (e.g., milrinone, dobutamine, epinephrine)~4. Permanent right ventricular assist device at the time of LVAD implant~5. Patients with a mechanical heart valve~6. Patients with end-stage renal disease on dialysis~7. Pregnant patients~8. Known history of ischemic stroke, intracranial bleed, or neurosurgery within 3 months~9. Known history of intracerebral arteriovenous malformation, cerebral aneurysm or mass lesions of the central nervous system.~10. Recent (\<48 hours) or planned spinal or epidural anesthesia or puncture~11. Prior history of known thrombophilia (e.g., factor V Leiden, prothrombin gene mutation, protein C or S deficiency, antithrombin 3 deficiency, hyperhomocysteinemia, antiphospholipid antibody syndrome) or indication for higher INR goal (\>2.5) with warfarin.~12. Thrombolysis within the previous 7 days~13. Patients with an allergy or contraindication to aspirin, warfarin, or apixaban~14. Patients on antiplatelet therapy other than aspirin (e.g., clopidogrel, prasugrel, ticagrelor, dipyridamole, or pentoxifylline)~15. Patients on combined P-glycoprotein and strong CPY3A4 inhibitors or inducers (e.g., fluconazole, posaconazole, rifampin)~16. Known bleeding within the last 30 days requiring emergency room presentation or hospitalization~17. Known history of an inherited bleeding disorder (e.g., hemophilia, von Willebrand disease)~18. Patients with active bleeding or a hemoglobin \< 8.0 g/dl~19. Total bilirubin \> 2.0 mg/dl, shock liver, hepatic encephalopathy, or biopsy proven liver cirrhosis~20. INR \> 2.0 not due to anticoagulation therapy~21. Platelet count \<100,000 cells/mm3

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Apixaban (Type: EXPERIMENTAL): LVAD patients randomized to the experimental arm will be prescribed apixaban 5 mg twice daily.
- Warfarin (Type: ACTIVE_COMPARATOR): LVAD patients randomized to the control arm will be prescribed warfarin which will be dosed to achieve an INR goal of 2-2.5

Based on this trial design, predict the completion outcome and termination type (if applicable).